US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
AU2004200325B2
(en)
*
|
1998-10-21 |
2006-09-28 |
Shire Llc |
Oral Pulsed Dose Drug Delivery System
|
US20010055613A1
(en)
|
1998-10-21 |
2001-12-27 |
Beth A. Burnside |
Oral pulsed dose drug delivery system
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20080102121A1
(en)
*
|
1998-11-02 |
2008-05-01 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
|
DK1126826T6
(en)
*
|
1998-11-02 |
2019-06-24 |
Alkermes Pharma Ireland Ltd |
Multiparticulate modified release of methylphenidate
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US7083808B2
(en)
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
AU755502C
(en)
*
|
1999-03-24 |
2003-08-14 |
Secretary Of State For Defence, The |
Immunostimulants
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
US6500462B1
(en)
*
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
NZ529928A
(en)
|
1999-10-29 |
2005-10-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
ES2258072T3
(es)
|
2000-01-19 |
2006-08-16 |
Mannkind Corporation |
Preparacion de liberacion en varias etapas para la administracion de medicamentos.
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
DE60121925T2
(de)
*
|
2000-03-22 |
2007-03-01 |
The Secretary Of State For Defence, Salisbury |
Arzneimittel zur verabreichung an schleimhäute
|
EP1280533A2
(de)
*
|
2000-05-11 |
2003-02-05 |
Pharmacia Corporation |
Aldosteronantagonist zusammensetzung zur freigabe während aldosteronakrophase
|
US6500457B1
(en)
*
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
CA2420535A1
(en)
*
|
2000-08-30 |
2002-03-07 |
Mary Tanya Am Ende |
Sustained release formulations for growth hormone secretagogues
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6344215B1
(en)
*
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
KR101045144B1
(ko)
|
2000-10-30 |
2011-06-30 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
IT1319655B1
(it)
|
2000-11-15 |
2003-10-23 |
Eurand Int |
Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
WO2002064654A1
(fr)
*
|
2001-02-09 |
2002-08-22 |
Reika Kogyo Kabushiki Kaisha |
Particule fonctionnelle, procede de preparation de celle-ci et procede de traitement par plasma
|
US20030190360A1
(en)
*
|
2001-03-13 |
2003-10-09 |
Baichwal Anand R. |
Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
|
AU2002256092C1
(en)
*
|
2001-04-05 |
2009-10-15 |
Collagenex Pharmaceuticals, Inc. |
Controlled delivery of tetracycline compounds and tetracycline derivatives
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
CN1610551A
(zh)
*
|
2001-07-06 |
2005-04-27 |
恩德制药公司 |
用作止痛剂的6-羟基羟吗啡酮的肠胃外给药
|
US20060263401A1
(en)
*
|
2001-07-13 |
2006-11-23 |
Flow Focusing, Inc. |
Formulation and Method for Preventing Infection
|
US20070254009A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic/bone morphogenic protein formulation and method of treatment
|
US20030055075A1
(en)
*
|
2001-07-13 |
2003-03-20 |
Rubsamen Reid M. |
Programmable controlled release injectable opioid formulation
|
US20070254008A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic formulation and method of treatment
|
US20040142013A1
(en)
*
|
2001-07-13 |
2004-07-22 |
Flow Focusing, Inc. |
Implantable orthopedic surgical devices with controlled release antimicrobial component
|
WO2003005996A1
(en)
*
|
2001-07-13 |
2003-01-23 |
Flow Focusing, Inc. |
Programmable controlled release injectable opioid formulation
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
US20030068375A1
(en)
*
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
ATE431738T1
(de)
|
2001-08-06 |
2009-06-15 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
WO2003026743A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
AUPR839001A0
(en)
*
|
2001-10-19 |
2001-11-15 |
Eli Lilly And Company |
Dosage form, device and methods of treatment
|
US20060281797A1
(en)
*
|
2001-12-11 |
2006-12-14 |
University Of Virginia Patent Foundation |
Neurorestoration with R(+) Pramipexole
|
KR20040066890A
(ko)
*
|
2001-12-11 |
2004-07-27 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
AU2003209475A1
(en)
*
|
2002-03-07 |
2003-09-16 |
Vectura Limited |
Fast melt multiparticulate formulations for oral delivery
|
WO2003084517A2
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Suspension orale de microcapsules d’amoxicilline
|
PT1492511E
(pt)
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
US7053034B2
(en)
*
|
2002-04-10 |
2006-05-30 |
Salvona, Llc |
Targeted controlled delivery compositions activated by changes in pH or salt concentration
|
CA2395819A1
(en)
*
|
2002-08-13 |
2004-02-13 |
Bernard Charles Sherman |
Dual-spike release formulation for oral drug delivery
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
WO2004034959A2
(en)
*
|
2002-09-18 |
2004-04-29 |
Elan Corporation, Plc |
Multiparticulate modified release composition comprising beraprost
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US20050191244A1
(en)
*
|
2002-10-25 |
2005-09-01 |
Gruenenthal Gmbh |
Abuse-resistant pharmaceutical dosage form
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
US20050038042A1
(en)
*
|
2002-11-15 |
2005-02-17 |
Jenet Codd |
Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
|
GB0228571D0
(en)
|
2002-12-06 |
2003-01-15 |
Novartis Ag |
Organic compounds
|
US7988993B2
(en)
*
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
DK1575569T3
(da)
|
2002-12-13 |
2011-01-10 |
Durect Corp |
Oralt indgivelsessystem omfattende flydende bærematerialer med høj viskositet
|
CA2510465A1
(en)
*
|
2002-12-18 |
2004-07-08 |
Pain Therapeutics |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
AU2003303631B2
(en)
*
|
2002-12-26 |
2008-05-29 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company |
Multilayer Dosage Forms Containing NSAIDs and Triptans
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7153526B2
(en)
*
|
2003-02-26 |
2006-12-26 |
Frank Steven R |
Treatment of gastrointestinal infections
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
US20040192781A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Haley Eugene T. |
Method of administration for metoclopramide and pharmaceutical formulation therefor
|
US20050137265A1
(en)
*
|
2003-03-31 |
2005-06-23 |
Haley Eugene T. |
Rapidly dissolving metoclopramide solid oral dosage and method thereof
|
MXPA05010636A
(es)
*
|
2003-04-04 |
2005-12-12 |
Pharmacia Corp |
Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
|
PL1615622T3
(pl)
|
2003-04-07 |
2012-12-31 |
Supernus Pharmaceuticals Inc |
Preparaty doksycyklin do jednorazowego dziennego podawania
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
WO2004100929A1
(en)
|
2003-05-12 |
2004-11-25 |
Synergia Pharma, Inc. |
Threo-dops controlled release formulation
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
CA2533178C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005009364A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005016311A1
(en)
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
AU2004264356B2
(en)
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
WO2005016317A1
(en)
*
|
2003-08-19 |
2005-02-24 |
Themis Laboratories Private Limited |
Process for manufacture of extended release pellets containing diltiazem hci
|
JP5686494B2
(ja)
|
2003-08-29 |
2015-03-18 |
シオノギ インコーポレイテッド |
抗生物質製剤、その使用法及び作成方法
|
AU2004270188B8
(en)
*
|
2003-09-03 |
2010-04-29 |
Mallinckrodt Inc. |
Granular sustained release preparation and production thereof
|
EP1663169A4
(de)
|
2003-09-15 |
2010-11-24 |
Middlebrook Pharmaceuticals In |
Antibiotisches produkt, seine verwendung und formulierung
|
US7906125B2
(en)
*
|
2003-09-18 |
2011-03-15 |
Boston Scientific Scimed, Inc. |
Solid or semi-solid therapeutic formulations
|
US20050118267A1
(en)
*
|
2003-09-19 |
2005-06-02 |
Penwest Pharmaceuticals Co. |
Chronotherapeutic dosage forms
|
NZ545921A
(en)
*
|
2003-09-19 |
2009-09-25 |
Penwest Pharmaceuticals Co |
Delayed released dosage forms
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US20050220873A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
EP1768668A2
(de)
|
2004-06-16 |
2007-04-04 |
Tap Pharmaceutical Products, Inc. |
Multi-ppi-dosierform
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
ES2703874T3
(es)
*
|
2004-08-23 |
2019-03-12 |
Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg |
Psicoestimulante que contiene una composición farmacéutica
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US9149472B2
(en)
|
2004-08-31 |
2015-10-06 |
Jack William Schultz |
Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
GB0421121D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Natrocell Technologies Ltd |
Composite rodenticide
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
US8962023B2
(en)
|
2004-09-28 |
2015-02-24 |
Atrium Medical Corporation |
UV cured gel and method of making
|
WO2006036967A1
(en)
|
2004-09-28 |
2006-04-06 |
Atrium Medical Corporation |
Solubilizing a drug for use in a coating
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
US20060078621A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Wedinger Robert S |
Method of providing customized drug delivery systems
|
NZ589750A
(en)
|
2004-10-21 |
2012-07-27 |
Aptalis Pharmatech Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
AR051654A1
(es)
*
|
2004-11-04 |
2007-01-31 |
Astrazeneca Ab |
Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
|
AR052225A1
(es)
*
|
2004-11-04 |
2007-03-07 |
Astrazeneca Ab |
Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
EA200701065A1
(ru)
*
|
2004-11-16 |
2007-12-28 |
Элан Фарма Интернэшнл Лтд. |
Инъецируемые составы, содержащие нанодисперсный оланзапин
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
US20060127421A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Celgene Corporation |
Treatment using D-threo methylphenidate
|
JP2008524239A
(ja)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミティド |
ナノ粒子のタクロリムス製剤
|
US20060269596A1
(en)
*
|
2005-01-12 |
2006-11-30 |
Gary Liversidge |
Controlled release compositions comprising an acylanilide
|
WO2006081347A2
(en)
*
|
2005-01-26 |
2006-08-03 |
Elan Pharma International Limited |
Controlled release compositions comprising an antipsychotic agent
|
GB0501809D0
(en)
*
|
2005-01-28 |
2005-03-09 |
Pharmakodex Ltd |
Anti-migraine formulations
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
WO2006087394A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
US20080254114A1
(en)
*
|
2005-03-03 |
2008-10-16 |
Elan Corporation Plc |
Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
|
CN101111230B
(zh)
*
|
2005-03-29 |
2010-05-19 |
赢创罗姆有限责任公司 |
包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
|
CN101171000A
(zh)
*
|
2005-04-12 |
2008-04-30 |
依兰药物国际有限公司 |
包含环孢菌素的毫微粒和控制释放组合物
|
CA2604192A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
|
WO2006110807A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
WO2006113310A2
(en)
*
|
2005-04-13 |
2006-10-26 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
JP2009514989A
(ja)
*
|
2005-05-10 |
2009-04-09 |
エラン コーポレーション ピーエルシー |
改変放出ロキソプロフェン組成物
|
EP1915139A1
(de)
*
|
2005-05-16 |
2008-04-30 |
Elan Pharma International Limited |
Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit einem cephalosporin
|
JP2008545808A
(ja)
*
|
2005-05-23 |
2008-12-18 |
エラン・ファルマ・インターナショナル・リミテッド |
血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
|
US20100136106A1
(en)
*
|
2005-06-08 |
2010-06-03 |
Gary Liversidge |
Modified Release Famciclovir Compositions
|
JP2009517485A
(ja)
|
2005-06-08 |
2009-04-30 |
エラン・ファルマ・インターナショナル・リミテッド |
セフジトレンを含むナノ粒子状および制御放出組成物
|
JP2009516636A
(ja)
*
|
2005-06-13 |
2009-04-23 |
エラン コーポレーション ピーエルシー |
改変放出チクロピジン組成物
|
WO2006138571A2
(en)
|
2005-06-16 |
2006-12-28 |
Mohammed Saeed |
Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
|
CA2613474A1
(en)
*
|
2005-06-20 |
2007-03-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
|
JP5095615B2
(ja)
|
2005-06-27 |
2012-12-12 |
バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ |
ブプロピオン塩の放出調整製剤
|
WO2007012856A1
(en)
*
|
2005-07-28 |
2007-02-01 |
University Of Hull |
Uses of sporopollenin
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
WO2007022182A1
(en)
*
|
2005-08-15 |
2007-02-22 |
University Of Virginia Patent Foundation |
Neurorestoration with r(+) pramipexole
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
FR2891459B1
(fr)
*
|
2005-09-30 |
2007-12-28 |
Flamel Technologies Sa |
Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
|
CN101374507A
(zh)
*
|
2005-10-14 |
2009-02-25 |
H.隆德贝克有限公司 |
含有依他普仑和安非他酮的稳定药物制剂
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
CA2626030A1
(en)
|
2005-10-15 |
2007-04-26 |
Atrium Medical Corporation |
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
|
US20070098791A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
|
US20070098796A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
|
EA017290B1
(ru)
*
|
2005-11-28 |
2012-11-30 |
Домейн Раша Инвестментс Лимитед |
Композиции на основе ганаксолона
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US20070134322A1
(en)
*
|
2005-12-14 |
2007-06-14 |
Forest Laboratories, Inc. |
Modified and pulsatile release pharmaceutical formulations of escitalopram
|
US20070141147A1
(en)
*
|
2005-12-21 |
2007-06-21 |
Auriga Laboratories, Inc. |
Sequential release pharmaceutical formulations
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
KR100753480B1
(ko)
*
|
2006-01-27 |
2007-08-31 |
씨제이 주식회사 |
잘토프로펜 함유 서방성 정제 및 그 제조방법
|
EP1976492B8
(de)
*
|
2006-01-27 |
2018-07-04 |
Adare Pharmaceuticals, Inc. |
Wirkstofffreisetzungssysteme mit leicht basischen wirkstoffen und organischen säuren
|
KR100762847B1
(ko)
*
|
2006-01-27 |
2007-10-04 |
씨제이 주식회사 |
멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
|
ES2531215T3
(es)
*
|
2006-01-27 |
2015-03-11 |
Aptalis Pharmatech Inc |
Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
|
ZA200807111B
(en)
|
2006-02-09 |
2009-11-25 |
Alba Therapeutics Corp |
Formulations for a tight junction effector
|
KR20070091960A
(ko)
*
|
2006-03-08 |
2007-09-12 |
주식회사종근당 |
졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
CN101400343B
(zh)
|
2006-03-16 |
2012-01-11 |
特瑞斯制药股份有限公司 |
含有药物-离子交换树脂复合物的经修饰释放的制剂
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US8518926B2
(en)
*
|
2006-04-10 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Compositions and methods of using (R)-pramipexole
|
US20070253927A1
(en)
*
|
2006-04-13 |
2007-11-01 |
Gwenaelle Jegou |
Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
|
US20070243252A1
(en)
*
|
2006-04-17 |
2007-10-18 |
Actavis Group Ptc Hf |
Oral Dosage Formulations and Methods of Preparing the Same
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
CA2652251A1
(en)
|
2006-05-16 |
2007-11-29 |
Knopp Neurosciences, Inc. |
Compositions of r(+) and s(-) pramipexole and methods for using the same
|
WO2007136663A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Flow Focusing, Inc. |
Antibiotic/bone morphogenic protein formulation and method of treatment
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
AU2007260821B2
(en)
*
|
2006-06-23 |
2012-06-21 |
Alkermes Pharma Ireland Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
EP2032139A4
(de)
*
|
2006-06-23 |
2012-08-22 |
Elan Pharma Int Ltd |
Zusammensetzungen mit nanoteilchenförmigem meloxicam und hydrocodon mit kontrollierter freisetzung
|
KR20090031618A
(ko)
*
|
2006-07-12 |
2009-03-26 |
엘란 코포레이션, 피엘씨 |
나노입자형 모다피닐 제제
|
US20080075771A1
(en)
*
|
2006-07-21 |
2008-03-27 |
Vaughn Jason M |
Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
|
US8889184B2
(en)
*
|
2006-09-07 |
2014-11-18 |
Losan Pharma Gmbh |
Particulate form of a pharmaceutical composition which is easy to swallow
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
CA2661683C
(en)
*
|
2006-08-31 |
2015-11-24 |
Eurand, Inc |
Drug delivery systems comprising solid solutions of weakly basic drugs
|
US20080064694A1
(en)
*
|
2006-09-11 |
2008-03-13 |
Auriga Laboratories, Inc. |
Multi-Phase Release Methscopolamine Compositions
|
US20080069874A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Auriga Laboratories, Inc. |
Kits for Prevention and Treatment of Rhinitis
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20080085312A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Auriga Laboratories, Inc. |
Multi-Phase Release Potassium Guaiacolsulfonate Compositions
|
WO2008043107A2
(en)
*
|
2006-10-06 |
2008-04-10 |
Alba Therapeutics Corporation |
Use of tight junction antagonists to treat inflammatory bowel disease
|
PL2124556T3
(pl)
|
2006-10-09 |
2015-02-27 |
Charleston Laboratories Inc |
Kompozycje farmaceutyczne
|
WO2008052185A2
(en)
*
|
2006-10-26 |
2008-05-02 |
Alba Therapeutics Corp |
Materials and methods for the treatment of celiac disease
|
US8642083B2
(en)
*
|
2006-10-30 |
2014-02-04 |
Hanall Biopharma Co., Ltd. |
Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
|
US20110212175A1
(en)
*
|
2006-10-30 |
2011-09-01 |
Hanall Biopharma Co., Ltd. |
Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
|
US8394845B2
(en)
*
|
2006-10-30 |
2013-03-12 |
Hanall Biopharma Co., Ltd. |
Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
WO2008057344A2
(en)
|
2006-11-06 |
2008-05-15 |
Atrium Medical Corporation |
Coated surgical mesh
|
AU2007319141B2
(en)
|
2006-11-17 |
2013-01-10 |
Supernus Pharmaceuticals Inc. |
Sustained-release formulations of topiramate
|
CN101534795B
(zh)
|
2006-11-21 |
2013-04-03 |
麦克内尔-Ppc股份有限公司 |
改进释放的镇痛悬浮液
|
JP2010510988A
(ja)
*
|
2006-11-28 |
2010-04-08 |
マリナス ファーマシューティカルズ |
ナノ粒子製剤とその製造方法およびその利用
|
CN102114002B
(zh)
*
|
2006-12-04 |
2016-05-11 |
苏佩努斯制药公司 |
托吡酯的增强的立即释放制剂
|
US8524695B2
(en)
*
|
2006-12-14 |
2013-09-03 |
Knopp Neurosciences, Inc. |
Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
|
PL2079445T3
(pl)
|
2007-02-20 |
2016-04-29 |
Allergan Pharmaceuticals Int Ltd |
Stabilne kompozycje enzymów trawiennych
|
WO2008106571A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Abbott Laboratories |
Sustained release parenteral formulations of buprenorphine
|
US8519148B2
(en)
|
2007-03-14 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Synthesis of chirally purified substituted benzothiazole diamines
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20080318994A1
(en)
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20090060983A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
US20090110716A1
(en)
|
2007-10-31 |
2009-04-30 |
Frank Bunick |
Orally disintegrative dosage form
|
AU2008347158B8
(en)
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
KR101569604B1
(ko)
|
2007-12-28 |
2015-11-16 |
임팩스 라보라토리즈, 인코포레이티드 |
레보도파 방출 제어형 제제 및 이의 용도
|
EP2240022B1
(de)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Oxycodone und Promethazine enthaltende zweischichtige Tabletten
|
US20100137442A2
(en)
*
|
2008-02-01 |
2010-06-03 |
Xenoport, Inc. |
Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
|
US10087493B2
(en)
|
2008-03-07 |
2018-10-02 |
Aptalis Pharma Canada Ulc |
Method for detecting infectious parvovirus in pharmaceutical preparations
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
AU2009223061B2
(en)
*
|
2008-03-11 |
2014-10-09 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8133506B2
(en)
*
|
2008-03-12 |
2012-03-13 |
Aptalis Pharmatech, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
CA2627198A1
(en)
*
|
2008-03-27 |
2009-09-27 |
Pharmascience Inc. |
Methylphenidate extended release therapeutic drug delivery system
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
GB0812513D0
(en)
*
|
2008-07-09 |
2008-08-13 |
Univ Hull |
Delivery vehicle
|
KR20110071064A
(ko)
|
2008-08-19 |
2011-06-28 |
크놉 뉴로사이언시스 인코포레이티드 |
(r)-프라미펙솔을 사용하는 조성물 및 방법
|
DE102008048729A1
(de)
*
|
2008-09-24 |
2010-03-25 |
Add Technologies Ltd Advanced Drug Delivery |
Multipartikuläre Tabletten und Verfahren zur deren Herstellung
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
AU2009311877C1
(en)
*
|
2008-11-07 |
2013-08-15 |
Samyang Holdings Corporation |
Pharmaceutical composition for release control of methylphenidate
|
CN102245171A
(zh)
*
|
2008-11-10 |
2011-11-16 |
株式会社爱茉莉太平洋 |
缓释微粒及其制备方法
|
US8551517B2
(en)
*
|
2008-12-16 |
2013-10-08 |
Kimberly-Clark Worldwide, Inc. |
Substrates providing multiple releases of active agents
|
BRPI0923836A2
(pt)
|
2008-12-31 |
2015-07-21 |
Upsher Smith Lab Inc |
Composições farmacêuticas orais contendo opióide e métodos
|
MX348282B
(es)
|
2009-02-13 |
2017-06-05 |
Romark Laboratories L C * |
Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
|
WO2010099508A1
(en)
|
2009-02-26 |
2010-09-02 |
Theraquest Biosciences, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
US20100260858A1
(en)
*
|
2009-04-09 |
2010-10-14 |
Elan Pharma International Limited |
Drug delivery composition
|
US20110223201A1
(en)
*
|
2009-04-21 |
2011-09-15 |
Selecta Biosciences, Inc. |
Immunonanotherapeutics Providing a Th1-Biased Response
|
AU2010239082B2
(en)
*
|
2009-04-24 |
2014-10-16 |
Iceutica Pty Ltd |
A novel formulation of metaxalone
|
AU2010254550B2
(en)
*
|
2009-05-27 |
2015-10-15 |
Selecta Biosciences, Inc. |
Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
WO2011006012A1
(en)
|
2009-07-08 |
2011-01-13 |
Charleston Laboratories Inc. |
Pharmaceutical compositions
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
KR20120059582A
(ko)
*
|
2009-08-31 |
2012-06-08 |
데포메드 인코퍼레이티드 |
아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
|
EP2477610A1
(de)
|
2009-09-17 |
2012-07-25 |
Upsher-Smith Laboratories, Inc. |
Verzögert freigesetztes produkt mit einer kombination aus einem nichtopioiden amin und einem nichtsteroiden entzündungshemmenden mittel
|
US8858210B2
(en)
|
2009-09-24 |
2014-10-14 |
Mcneil-Ppc, Inc. |
Manufacture of variable density dosage forms utilizing radiofrequency energy
|
US20110070286A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Andreas Hugerth |
Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
|
US8313768B2
(en)
|
2009-09-24 |
2012-11-20 |
Mcneil-Ppc, Inc. |
Manufacture of tablet having immediate release region and sustained release region
|
US8784781B2
(en)
*
|
2009-09-24 |
2014-07-22 |
Mcneil-Ppc, Inc. |
Manufacture of chewing gum product with radiofrequency
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
JP5309262B2
(ja)
|
2009-12-02 |
2013-10-09 |
アプタリス ファーマ リミテッド |
フェキソフェナジン・マイクロカプセル及びそれを含む組成物
|
SG181797A1
(en)
|
2009-12-18 |
2012-07-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
US9186642B2
(en)
|
2010-04-28 |
2015-11-17 |
The Procter & Gamble Company |
Delivery particle
|
US9993793B2
(en)
|
2010-04-28 |
2018-06-12 |
The Procter & Gamble Company |
Delivery particles
|
EP2568977A1
(de)
|
2010-05-11 |
2013-03-20 |
Cima Labs Inc. |
Alkoholresistente metoprololhaltige orale retard-dosierformen
|
WO2011146583A2
(en)
|
2010-05-19 |
2011-11-24 |
Elan Pharma International Limited |
Nanoparticulate cinacalcet formulations
|
AU2011258156B2
(en)
|
2010-05-26 |
2016-11-24 |
Selecta Biosciences, Inc. |
Multivalent synthetic nanocarrier vaccines
|
KR101872189B1
(ko)
*
|
2010-06-16 |
2018-06-29 |
다케다 파마슈티칼스 유에스에이, 인코포레이티드 |
크산틴 옥시도리덕타제 억제제 또는 크산틴 옥시다제 억제제의 신규한 조절 방출 제형
|
WO2012009707A2
(en)
|
2010-07-16 |
2012-01-19 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
JP5872558B2
(ja)
|
2010-09-01 |
2016-03-01 |
アムビト ビオスシエンセス コルポラチオン |
ピラゾリルアミノキナゾリンの臭化水素酸塩
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
CN101933913A
(zh)
*
|
2010-09-16 |
2011-01-05 |
孙卫东 |
一种盐酸右哌甲酯双释放制剂及其制备方法
|
WO2012040710A2
(en)
*
|
2010-09-24 |
2012-03-29 |
Case Western Reserve University |
Stabilized nanobubbles for diagnostic and therapeutic applications
|
KR101968457B1
(ko)
|
2010-10-01 |
2019-04-11 |
앨러간 파마슈티컬스 인터내셔널 리미티드 |
장용 코팅된 저 강도 췌장 리파제 제제
|
WO2012078649A1
(en)
|
2010-12-06 |
2012-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
WO2012106299A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
WO2012129551A1
(en)
|
2011-03-23 |
2012-09-27 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods and compositions for treatment of attention deficit disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
CA2830948A1
(en)
*
|
2011-03-25 |
2012-10-04 |
Selecta Biosciences, Inc. |
Osmotic mediated release synthetic nanocarriers
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US8980292B2
(en)
|
2011-04-07 |
2015-03-17 |
The Procter & Gamble Company |
Conditioner compositions with increased deposition of polyacrylate microcapsules
|
JP6283607B2
(ja)
|
2011-04-07 |
2018-02-21 |
ザ プロクター アンド ギャンブル カンパニー |
ポリアクリレートマイクロカプセルの堆積が増大されたパーソナルクレンジング組成物
|
CN103458858B
(zh)
|
2011-04-07 |
2016-04-27 |
宝洁公司 |
具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
AU2012290306B2
(en)
|
2011-07-29 |
2017-08-17 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
|
RU2016119726A
(ru)
|
2011-08-08 |
2018-11-02 |
Апталис Фарма Лтд. |
Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
|
US9512096B2
(en)
|
2011-12-22 |
2016-12-06 |
Knopp Biosciences, LLP |
Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
CN102429884A
(zh)
*
|
2011-12-29 |
2012-05-02 |
天津市嵩锐医药科技有限公司 |
盐酸哌甲酯口腔崩解药物组合物
|
CN104302640A
(zh)
|
2012-03-16 |
2015-01-21 |
埃克希金医药品有限公司 |
3,5-二氨基吡唑激酶抑制剂
|
US9445971B2
(en)
|
2012-05-01 |
2016-09-20 |
Johnson & Johnson Consumer Inc. |
Method of manufacturing solid dosage form
|
US9511028B2
(en)
|
2012-05-01 |
2016-12-06 |
Johnson & Johnson Consumer Inc. |
Orally disintegrating tablet
|
US9233491B2
(en)
|
2012-05-01 |
2016-01-12 |
Johnson & Johnson Consumer Inc. |
Machine for production of solid dosage forms
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
JP5715303B2
(ja)
|
2012-06-15 |
2015-05-07 |
公益財団法人先端医療振興財団 |
軽度認知障害の予防および/または治療剤
|
ES2698611T3
(es)
|
2012-07-12 |
2019-02-05 |
SpecGx LLC |
Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada
|
US20140161879A1
(en)
*
|
2012-07-31 |
2014-06-12 |
Zogenix, Inc. |
Treating pain in patients with hepatic impairment
|
US10322120B2
(en)
|
2012-07-31 |
2019-06-18 |
Persion Pharmaceuticals Llc |
Treating pain in patients with hepatic impairment
|
EP2884961B1
(de)
|
2012-08-15 |
2019-03-06 |
Tris Pharma Inc. |
Methylphenidat-kautablette mit verlängerter freisetzung
|
US9662313B2
(en)
|
2013-02-28 |
2017-05-30 |
Knopp Biosciences Llc |
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
CN105120659A
(zh)
|
2013-03-15 |
2015-12-02 |
度瑞公司 |
用于降低溶解可变性的具有流变改性剂的组合物
|
WO2014174387A1
(en)
|
2013-03-29 |
2014-10-30 |
Wockhardt Limited |
Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
|
US10434194B2
(en)
|
2013-06-20 |
2019-10-08 |
Case Western Reserve University |
PSMA targeted nanobubbles for diagnostic and therapeutic applications
|
US10184121B2
(en)
|
2013-06-28 |
2019-01-22 |
Allergan Pharmaceuticals International Limited |
Methods for removing viral contaminants from pancreatic extracts
|
RS61539B1
(sr)
|
2013-07-12 |
2021-04-29 |
Knopp Biosciences Llc |
Lečenje povišenih nivoa eozinofila i/ili bazofila
|
US9468630B2
(en)
|
2013-07-12 |
2016-10-18 |
Knopp Biosciences Llc |
Compositions and methods for treating conditions related to increased eosinophils
|
ES2784227T3
(es)
|
2013-08-09 |
2020-09-23 |
Allergan Pharmaceuticals Int Ltd |
Composición de enzimas digestivos adecuada para la administración entérica
|
WO2015023786A1
(en)
|
2013-08-13 |
2015-02-19 |
Knopp Biosciences Llc |
Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
|
CA2921381A1
(en)
|
2013-08-13 |
2015-02-19 |
Knopp Biosciences Llc |
Compositions and methods for treating chronic urticaria
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
EP3782614A1
(de)
|
2013-10-07 |
2021-02-24 |
Impax Laboratories, LLC |
Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
CA2928899C
(en)
*
|
2013-11-04 |
2021-02-16 |
Jack William SCHULTZ |
Treatment of cognitive, emotional and mental ailments and disorders
|
ES2750323T3
(es)
|
2014-01-10 |
2020-03-25 |
Johnson & Johnson Consumer Inc |
Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida
|
EP3114122A1
(de)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Feste formen einer flaviviridae-virus-hemmerverbindung und salze davon
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
CA2943220C
(en)
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
KR101686986B1
(ko)
*
|
2014-07-28 |
2016-12-16 |
에스케이케미칼주식회사 |
류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
US9795571B2
(en)
|
2014-09-19 |
2017-10-24 |
The Procter & Gamble Company |
Pulsed release phenylephrine dosage forms
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
GB201420306D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Compositions
|
KR20170086659A
(ko)
*
|
2014-12-03 |
2017-07-26 |
벨리셉트 테라퓨틱스, 인크. |
하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
KR20180082457A
(ko)
|
2015-10-16 |
2018-07-18 |
마리누스 파마슈티컬스 인코포레이티드 |
나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
|
FI3365321T3
(fi)
|
2015-10-23 |
2024-01-02 |
B3Ar Therapeutics Inc |
Solabegron-Zwitterioni ja sen käyttöjä
|
US20170296476A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Grünenthal GmbH |
Modified release abuse deterrent dosage forms
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
WO2017210696A1
(en)
*
|
2016-06-03 |
2017-12-07 |
Velicept Therapeutics, Inc. |
Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
|
JP2019524816A
(ja)
|
2016-08-11 |
2019-09-05 |
オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. |
てんかん性障害の処置のための方法および組成物
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
EP3585439A4
(de)
|
2016-11-01 |
2020-07-22 |
Neos Therapeutics, LP |
Wirksame dosierung für kinder zur behandlung von adhd mit methylphenidat
|
US10278930B2
(en)
|
2017-03-16 |
2019-05-07 |
The Procter & Gamble Company |
Method for relieving sinus congestion
|
US10493026B2
(en)
|
2017-03-20 |
2019-12-03 |
Johnson & Johnson Consumer Inc. |
Process for making tablet using radiofrequency and lossy coated particles
|
WO2018172998A1
(en)
*
|
2017-03-23 |
2018-09-27 |
Instituto De Capacitación E Investigación Del Plástico Y Del Caucho |
Dietary supplement derived from natural products by hot melt extrusion (hme) processing
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
US20190381056A1
(en)
|
2018-06-17 |
2019-12-19 |
Axsome Therapeutics, Inc. |
Compositions for delivery of reboxetine
|
US20200147093A1
(en)
|
2018-10-15 |
2020-05-14 |
Axsome Therapeutics, Inc. |
Use of esreboxetine to treat nervous system disorders such as fibromyalgia
|
US11020402B2
(en)
|
2018-10-15 |
2021-06-01 |
Axsome Therapeutics, Inc. |
Use of reboxetine to treat narcolepsy
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020104955A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Dr. Reddy’S Laboratories Limited |
Pharmaceutical compositions of acotiamide and proton pump inhibitor
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
EP3965733A4
(de)
|
2019-05-07 |
2023-01-11 |
Clexio Biosciences Ltd. |
Esketamin enthaltende missbrauchssichere darreichungsformen
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
KR20220134529A
(ko)
|
2019-12-06 |
2022-10-05 |
마리누스 파마슈티컬스 인코포레이티드 |
복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
|